Cognitive-behavioral management of chemotherapy-related cognitive change

Robert J. Ferguson, Tim A. Ahles, Andrew Saykin, Brenna McDonald, Charlotte T. Furstenberg, Bernard F. Cole, Leila A. Mott

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Adjuvant chemotherapy can produce mild cognitive decline among breast cancer survivors which adversely effects function and quality of life. However, no treatment to date has been proposed or developed for this problem despite large numbers of cancer patients who report post-treatment memory dysfunction. This paper presents data from a single arm pilot study of a brief cognitive-behavioral treatment aimed at helping breast cancer survivors manage cognitive dysfunction associated with adjuvant chemotherapy (Memory and Attention Adaptation Training; MAAT). Participants were twenty-nine women who were an average of 8 years post-chemotherapy for stage I and II breast cancer. All had reported complaints regarding memory and attention. Improvements in self-report of cognitive function, quality of life and standard neuropsychological test performance were observed at post-treatment, 2-month and 6-month follow-up. Participants also reported high treatment satisfaction and rated MAAT as helpful in improving ability to compensate for memory problems. Given these results, the treatment appears to be a feasible and practical cognitive-behavioral program that warrants continued evaluation among cancer survivors who experience persistent cognitive dysfunction.

Original languageEnglish (US)
Pages (from-to)772-777
Number of pages6
JournalPsycho-Oncology
Volume16
Issue number8
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

cancer
Drug Therapy
management
Survivors
Adjuvant Chemotherapy
Breast Neoplasms
quality of life
Therapeutics
Quality of Life
Aptitude
complaint
Neuropsychological Tests
Self Report
Cognition
Neoplasms
ability
evaluation
performance
experience
Cognitive Dysfunction

Keywords

  • Breast cancer
  • Chemotherapy
  • Cognitice-behavioral treatment
  • Cognitive dysfunction
  • Survivorship

ASJC Scopus subject areas

  • Oncology
  • Psychology(all)
  • Social Sciences (miscellaneous)

Cite this

Ferguson, R. J., Ahles, T. A., Saykin, A., McDonald, B., Furstenberg, C. T., Cole, B. F., & Mott, L. A. (2007). Cognitive-behavioral management of chemotherapy-related cognitive change. Psycho-Oncology, 16(8), 772-777. https://doi.org/10.1002/pon.1133

Cognitive-behavioral management of chemotherapy-related cognitive change. / Ferguson, Robert J.; Ahles, Tim A.; Saykin, Andrew; McDonald, Brenna; Furstenberg, Charlotte T.; Cole, Bernard F.; Mott, Leila A.

In: Psycho-Oncology, Vol. 16, No. 8, 08.2007, p. 772-777.

Research output: Contribution to journalArticle

Ferguson, RJ, Ahles, TA, Saykin, A, McDonald, B, Furstenberg, CT, Cole, BF & Mott, LA 2007, 'Cognitive-behavioral management of chemotherapy-related cognitive change', Psycho-Oncology, vol. 16, no. 8, pp. 772-777. https://doi.org/10.1002/pon.1133
Ferguson, Robert J. ; Ahles, Tim A. ; Saykin, Andrew ; McDonald, Brenna ; Furstenberg, Charlotte T. ; Cole, Bernard F. ; Mott, Leila A. / Cognitive-behavioral management of chemotherapy-related cognitive change. In: Psycho-Oncology. 2007 ; Vol. 16, No. 8. pp. 772-777.
@article{77a16e42b86e4ff28cf2fa62a22d9f28,
title = "Cognitive-behavioral management of chemotherapy-related cognitive change",
abstract = "Adjuvant chemotherapy can produce mild cognitive decline among breast cancer survivors which adversely effects function and quality of life. However, no treatment to date has been proposed or developed for this problem despite large numbers of cancer patients who report post-treatment memory dysfunction. This paper presents data from a single arm pilot study of a brief cognitive-behavioral treatment aimed at helping breast cancer survivors manage cognitive dysfunction associated with adjuvant chemotherapy (Memory and Attention Adaptation Training; MAAT). Participants were twenty-nine women who were an average of 8 years post-chemotherapy for stage I and II breast cancer. All had reported complaints regarding memory and attention. Improvements in self-report of cognitive function, quality of life and standard neuropsychological test performance were observed at post-treatment, 2-month and 6-month follow-up. Participants also reported high treatment satisfaction and rated MAAT as helpful in improving ability to compensate for memory problems. Given these results, the treatment appears to be a feasible and practical cognitive-behavioral program that warrants continued evaluation among cancer survivors who experience persistent cognitive dysfunction.",
keywords = "Breast cancer, Chemotherapy, Cognitice-behavioral treatment, Cognitive dysfunction, Survivorship",
author = "Ferguson, {Robert J.} and Ahles, {Tim A.} and Andrew Saykin and Brenna McDonald and Furstenberg, {Charlotte T.} and Cole, {Bernard F.} and Mott, {Leila A.}",
year = "2007",
month = "8",
doi = "10.1002/pon.1133",
language = "English (US)",
volume = "16",
pages = "772--777",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Cognitive-behavioral management of chemotherapy-related cognitive change

AU - Ferguson, Robert J.

AU - Ahles, Tim A.

AU - Saykin, Andrew

AU - McDonald, Brenna

AU - Furstenberg, Charlotte T.

AU - Cole, Bernard F.

AU - Mott, Leila A.

PY - 2007/8

Y1 - 2007/8

N2 - Adjuvant chemotherapy can produce mild cognitive decline among breast cancer survivors which adversely effects function and quality of life. However, no treatment to date has been proposed or developed for this problem despite large numbers of cancer patients who report post-treatment memory dysfunction. This paper presents data from a single arm pilot study of a brief cognitive-behavioral treatment aimed at helping breast cancer survivors manage cognitive dysfunction associated with adjuvant chemotherapy (Memory and Attention Adaptation Training; MAAT). Participants were twenty-nine women who were an average of 8 years post-chemotherapy for stage I and II breast cancer. All had reported complaints regarding memory and attention. Improvements in self-report of cognitive function, quality of life and standard neuropsychological test performance were observed at post-treatment, 2-month and 6-month follow-up. Participants also reported high treatment satisfaction and rated MAAT as helpful in improving ability to compensate for memory problems. Given these results, the treatment appears to be a feasible and practical cognitive-behavioral program that warrants continued evaluation among cancer survivors who experience persistent cognitive dysfunction.

AB - Adjuvant chemotherapy can produce mild cognitive decline among breast cancer survivors which adversely effects function and quality of life. However, no treatment to date has been proposed or developed for this problem despite large numbers of cancer patients who report post-treatment memory dysfunction. This paper presents data from a single arm pilot study of a brief cognitive-behavioral treatment aimed at helping breast cancer survivors manage cognitive dysfunction associated with adjuvant chemotherapy (Memory and Attention Adaptation Training; MAAT). Participants were twenty-nine women who were an average of 8 years post-chemotherapy for stage I and II breast cancer. All had reported complaints regarding memory and attention. Improvements in self-report of cognitive function, quality of life and standard neuropsychological test performance were observed at post-treatment, 2-month and 6-month follow-up. Participants also reported high treatment satisfaction and rated MAAT as helpful in improving ability to compensate for memory problems. Given these results, the treatment appears to be a feasible and practical cognitive-behavioral program that warrants continued evaluation among cancer survivors who experience persistent cognitive dysfunction.

KW - Breast cancer

KW - Chemotherapy

KW - Cognitice-behavioral treatment

KW - Cognitive dysfunction

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=34547855878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547855878&partnerID=8YFLogxK

U2 - 10.1002/pon.1133

DO - 10.1002/pon.1133

M3 - Article

C2 - 17152119

AN - SCOPUS:34547855878

VL - 16

SP - 772

EP - 777

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 8

ER -